The formation of multimolecular complexes called """"""""signalosomes"""""""" by A-kinase anchoring proteins (AKAPs) contributes to the spatial and temporal restriction of intracellular signaling by the second messenger cAMP. Targeting unique protein-protein interactions present within individual signalosomes may constitute a novel approach to drug discovery, yielding a new class of selective cardiac therapies displaying minimal off- target side-effects. One such signalosome is organized by mAKAPb, a scaffold protein that binds adenylyl cyclase 5, the cAMP-dependent enzymes protein kinase A and Epac1, and the cAMP-specific phosphodiesterase PDE4D3. By including all of the enzymes necessary for cAMP synthesis, degradation, and function, mAKAPb complexes may autonomously regulate and respond to locally controlled cAMP levels. mAKAPb signalosomes also contain ERK5 mitogen-activated protein kinase and the Ca2???? dependent phosphatase calcineurin Ab. Accordingly, the induction of neonatal myocyte hypertrophy in vitro by adrenergic and gp130 cytokine/leukemia inhibitory factor receptors is impaired by RNAi of mAKAPb expression. This application has three Specific Aims that address two central hypotheses: (1) that mAKAPb plays a critical role in the regulation of cardiac remodeling in vivo, and (2) that the mAKAPb signalosome forms an autonomous cAMP signaling compartment whose disruption will result in changes both in local cAMP levels and overall myocyte phenotype.
Specific Aim 1 : The role of mAKAPb in cardiac remodeling. The in vivo relevance of the mAKAPb scaffold to pathologic remodeling will be tested in mice using a new """"""""floxed"""""""" mAKAP allele. The mAKAP gene will be deleted using a cardiac-specific cre transgene, and both unstressed, aging mice and mice subjected to chronic isoproterenol infusion, transverse aortic constriction and myocardial infarction will be studied.
Specific Aim 2 : Regulation of AC5 by mAKAPb Complexes. AC5 directly binds to a N-terminal domain in mAKAPb. How AC5 activity is regulated by binding mAKAPb will be investigated in vitro and in vivo using a novel transgenic mouse in which an AC5-binding peptide is conditionally expressed in the heart.
Specific Aim 3 : Control of local cAMP levels by the mAKAPb signalosome. mAKAPb signalosome regulation of local cAMP levels in living cells will be investigated by the expression in cultured adult and neonatal cardiac myocytes of cAMP FRET sensors fused to mAKAPb. Signals obtained with a wildtype mAKAPb fusion sensor will be compared to that obtained using mAKAPb sensors lacking binding sites for individual binding partners, thereby revealing how the disruption of an individual scaffold protein complex affects intracellular signaling. Data obtained by these Specific Aims should establish the mAKAPb signalosome as an important node in the hypertrophic signaling network and as a candidate target for specific drug therapy for maladaptive remodeling and the prevention of heart failure.

Public Health Relevance

Heart failure is a syndrome of major public heath significance accountable for nearly 300,000 deaths each year. It is estimated that 5.7 million US citizens suffer from heart failure, with nearly 670,000 new cases diagnosed annually. A better understanding of the cellular mechanisms that control cardiac remodeling, including myocyte hypertrophy, may yield better therapeutic regimens with decreased mortality.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL075398-06A1
Application #
7983358
Study Section
Myocardial Ischemia and Metabolism Study Section (MIM)
Program Officer
Adhikari, Bishow B
Project Start
2003-12-08
Project End
2015-06-30
Budget Start
2010-07-15
Budget End
2011-06-30
Support Year
6
Fiscal Year
2010
Total Cost
$382,500
Indirect Cost
Name
University of Miami School of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
052780918
City
Coral Gables
State
FL
Country
United States
Zip Code
33146
Kapiloff, Michael S; Emter, Craig A (2016) The cardiac enigma: current conundrums in heart failure research. F1000Res 5:
Passariello, Catherine L; Martinez, Eliana C; Thakur, Hrishikesh et al. (2016) RSK3 is required for concentric myocyte hypertrophy in an activated Raf1 model for Noonan syndrome. J Mol Cell Cardiol 93:98-105
Martinez, Eliana C; Passariello, Catherine L; Li, Jinliang et al. (2015) RSK3: A regulator of pathological cardiac remodeling. IUBMB Life 67:331-7
Passariello, Catherine L; Li, Jinliang; Dodge-Kafka, Kimberly et al. (2015) mAKAP-a master scaffold for cardiac remodeling. J Cardiovasc Pharmacol 65:218-25
Kritzer, Michael D; Li, Jinliang; Passariello, Catherine L et al. (2014) The scaffold protein muscle A-kinase anchoring protein ? orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure. Circ Heart Fail 7:663-72
Kapiloff, Michael S; Rigatti, Marc; Dodge-Kafka, Kimberly L (2014) Architectural and functional roles of A kinase-anchoring proteins in cAMP microdomains. J Gen Physiol 143:9-15
Passariello, Catherine L; Gayanilo, Marjorie; Kritzer, Michael D et al. (2013) p90 ribosomal S6 kinase 3 contributes to cardiac insufficiency in *-tropomyosin Glu180Gly transgenic mice. Am J Physiol Heart Circ Physiol 305:H1010-9
Rusconi, Francesca; Thakur, Hrishikesh; Li, Jinliang et al. (2013) CIP4 is required for the hypertrophic growth of neonatal cardiac myocytes. J Biomed Sci 20:56
Li, Jinliang; Vargas, Maximilian A X; Kapiloff, Michael S et al. (2013) Regulation of MEF2 transcriptional activity by calcineurin/mAKAP complexes. Exp Cell Res 319:447-54
Li, Jinliang; Kritzer, Michael D; Michel, Jennifer J Carlisle et al. (2013) Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy. Circ Res 112:128-39

Showing the most recent 10 out of 30 publications